艾迪注射液联合TP化疗方案治疗晚期非小细胞肺癌的效果分析

Analysis on the Effect of Aidi Injection Combined with TP Chemotherapy Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨艾迪注射液联合紫杉醇+顺铂(TP)化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法选取2018年2月至2020年2月我院收治的60例晚期NSCLC患者,根据治疗方法的不同分为两组各30例。对照组采用TP化疗方案治疗,观察组采用艾迪注射液联合TP化疗方案治疗。比较两组的治疗效果及不良反应发生率。结果治疗2个疗程后,观察组的总缓解率、总控制率分别为53.33%、90.00%,显著高于对照组的23.33%、66.67%,差异有统计学意义(P<0.05)。治疗期间,两组的腹痛、腹泻、恶心、呕吐及白细胞下降发生率比较,差异无统计学意义(P>0.05)。结论艾迪注射液联合TP化疗方案可有效提升晚期NSCLC的临床疗效,且未明显增加不良反应。

Objective To explore the clinical effect of Aidi injection combined with paclitaxel+cisplatin(TP)chemotherapy regimen in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 60 patients with advanced NSCLC admitted to our hospital from February 2018 to February 2020 were selected and divided into two groups according to different treatment methods,with 30cases in each group.The control group was treated with TP chemotherapy regimen,and the observation group was treated with Aidi injection combined with TP chemotherapy regimen.The treatment effect and the incidences of adverse reactions were compared between the two groups.Results After 2 courses of treatment,the total remission rate and total control rate of the observation group were 53.33%and90.00%,significantly higher than 23.33%and 66.67%of the control group,respectively,with statistically significant differences(P<0.05).During the treatment,no significant difference was found in the incidences of abdominal pain,diarrhea,nausea,vomiting and leukopenia between the two groups(P>0.05).Conclusions Aidi injection combined with TP chemotherapy can effectively improve the clinical efficacy of advanced NSCLC without significantly increasing adverse reactions.